New hope for rare bone disease: drug raises low phosphate levels
NCT ID NCT05509595
First seen Feb 02, 2026 · Last updated May 02, 2026 · Updated 14 times
Summary
This study tested a drug called burosumab in 12 people with fibrous dysplasia, a rare bone disorder that can cause weak bones and low blood phosphate. The goal was to see if the drug could safely bring phosphate levels back to normal. Participants injected the drug at home once or twice a month for 48 weeks and had regular check-ups at the NIH.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA OF BONE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.